Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A new study has confirmed that weight loss or bariatric surgery is safe and very effective, and, for a large percentage of ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...